Abstract

Objective: To explore the relationship between drug disposition and clinical responses, focusing on key mechanisms and factors, and examines relevant studies to provide a comprehensive overview.
Methodology: This narrative review examined the link between clinical responses and drug disposition, focusing on the latest studies published in between 2015-2024.The study quality was checked by Grading of Recommendation Assessment, Development and Evaluation criteria.
Result: Genetic variations, physiological factors, and pathological conditions can impact drug disposition, leading to inter-individual differences. Gender-specification, pathological pharmacokinetic variations, and drug interactions are recommended for improved dosing practices. The frequencies of adverse-drug-reactions due to higher values of pharmacokinetics parameters were equal in both genders i.e., 59. Adverse-drug-reactions increased due to higher pharmacokinetics parameters were 96% in male and 29% in female. Drug disposition and clinical response variation were noted in anti-neoplastic drugs i.e., abiraterone, everolimus, imatinib, pazopanib, sunitinib and tamoxifen.
Conclusion: Pharmacokinetics of a drug helps in optimizing drug therapy, minimizes adverse-drug-reactions, toxicity risks and integrates data into clinical practices and regulatory frameworks, enhancing therapeutic outcomes and promoting personalized treatment regimens.

Key words: Drug disposition, clinical response, physiological changes, therapeutic response, adverse-drug-reactions.